A 2025 meta-analysis pooling several phase 2 randomised controlled trials involving more than 500 participants confirmed these findings, showing 1524% average weight loss across different doses and durations
Effects of glucagon-like peptide 1 (GLP-1) analogs in the hippocampus
However, while around 12% Americans use them and they are intended to be taken long-term, the majority stop taking them within a year
Early weeks are focused on gradual dose escalation to minimise side effects, so initial changes may be modest
In January 2025, researchers from Medication Weight Loss Clinic, Ireland, found that GLP-1 agonists showed positive results in managing co-occurring obesity and reducing alcohol intake
Accessible trials dont just drive recruitment, they protect patients, accelerate innovation, and close the space where unsafe products thrive